LivaNova director sales, Medtronic comparison, and $81.42

LivaNova PLC sits in a part of medtech that still gets paid for doing real work. Cardiopulmonary systems go into open-heart procedures. Neuromodulation sells into a slower, more clinical adoption cycle, with vagus nerve stimulation for drug-resistant epilepsy and an obstructive sleep apnea pipeline hanging off the side. That mix matters because the market has been willing to pay for durable procedure demand and visible guidance, especially while rate expectations have eased and healthcare has kept its defensive-growth bid.

Against that backdrop, the stock is not trading in a vacuum. The clean comparison is Medtronic and Boston Scientific, the larger names with broader portfolios and more ways to absorb a miss. LivaNova does not have that luxury. It has a narrower story, which can help when the operating numbers are moving the right way, and hurt when the market wants proof that the improvement is not just a quarter or two of clean air.

The insider filing lands in that context. Brooke Story, a director, sold 2,300 ordinary shares on September 4 at an average price of $81.4218, for about EUR 161,146 euro-normalised filing value. After the sale, Story retained 7,488 shares directly. The filing went to the SEC on September 8. A second director, Francesco Bianchi, sold 1,650 shares on August 31 at $79.72, for $131,538. Two sales in a short window are enough to make this a cluster, and cluster is the right word here because the market is not being asked to read one isolated disposal and move on.

Cardiopulmonary momentum is doing the heavy lifting

The first reason LivaNova deserves a comparison with a larger peer is that the operating print is not weak. In its August 5 second-quarter release, the company reported 10.8% revenue growth to $390.6 million and raised full-year 2026 constant-currency revenue guidance to 8% to 9%. Management also lifted adjusted diluted EPS guidance to $4.30 to $4.40. Those are not the numbers of a business in distress, and they are not the numbers of a board that should be selling into a collapse.

The cardiopulmonary segment is the part that gives the stock its industrial feel. Heart-lung machines and oxygenators are not glamorous products, but they are tied to procedure volumes and hospital demand that can be tracked. LivaNova also pointed to a long-term supply agreement with Thermo Fisher Scientific to address oxygenator component demand. That is the kind of operational detail that matters more than a slogan. It tells you the company is trying to keep supply from becoming the bottleneck in a business where execution is often more about consistency than surprise.

Medtronic and Boston Scientific have the advantage of scale, and scale buys patience. LivaNova has to earn it. That is why the market has been willing to give the shares a decent look near $80 to $82, but not a blank cheque. The stock can trade well on a clean quarter. It can also get judged more harshly if the next print shows that the growth is less broad than it looked.

The insider sale does not change that operating picture. It does, however, tell you where the board is choosing to take money off the table while the stock is near recent highs. Story sold at $81.4218, Bianchi sold at $79.72, and both sales came after the company had already put up a better revenue run rate. That is a very different read from a director buying weakness after a miss. You do not need to invent motive to see the difference.

Neuromodulation gives LivaNova optionality, and a peer gives context

LivaNova’s neuromodulation business is the part that keeps the story from being a pure cardiopulmonary trade. Vagus nerve stimulation for drug-resistant epilepsy is a real franchise, and the obstructive sleep apnea pipeline gives the market something to argue about beyond the current quarter. The problem, if you want to call it that, is that optionality is not the same thing as scale. Boston Scientific can layer growth across multiple franchises. Medtronic can lean on a broader device portfolio. LivaNova has to make each piece count.

That is why the peer comparison matters. Larger medtech names can absorb a slower patch in one line and still keep the market focused on the rest of the machine. LivaNova has fewer moving parts, so each one gets more attention. When management raises guidance, the stock can rerate. When directors sell into that rerating, the market notices because there are fewer distractions.

The broader healthcare tape has helped. Stable or improving central bank rate expectations have supported defensive growth areas, and earnings momentum has kept money flowing toward companies with visible procedural demand. LivaNova fits that pattern better than a lot of smaller medtech names because it has both a recurring procedural angle and a growth narrative. But the comparison with Medtronic still exposes the gap. Medtronic’s breadth gives it a different kind of resilience. LivaNova has to prove its own.

The recent declarations show four distinct insiders and 12 recent declarations, with Story appearing twice, Bianchi once, and Ahmet Tezel appearing in the record as well. The cluster is not a single dramatic dump. It is a series of smaller decisions around the same name. In a stock that has already had a good run, that is enough to make you ask whether the easy money has already been taken.

The filing is small, but the timing is not

Brooke Story’s sale was 2,300 ordinary shares. On its own, that is not a governance event. It is a director sale sized at a negligible fraction of the company’s market value, under 0.01%, and the filing value is about EUR 161,146. The company’s market cap in the dossier is EUR 3.769 billion. So no, this is not a balance-sheet move, and no, it is not a sign that the board is running for the exits.

But timing matters. Story sold on September 4, after the company had already reported a stronger quarter and after the shares had been trading near $80 to $82. Bianchi sold on August 31 at $79.72. Put those together and you get a pattern that looks more like monetization into strength than panic. That is not a moral judgment. It is just what the dates and prices say.

The market often overreads insider sales when the stock has already moved. Sometimes that is a mistake. Sometimes it is the only useful clue you get. Here, the sale is not large enough to dominate the thesis, but it is large enough to sit in the same sentence as the raised guidance and the recent share strength. That is the tension. The company is executing well enough to justify attention, and the insiders are still taking some chips off the table.

Our scoring puts weight on the fact that the filing came from an operating director, that it sits inside an insider cluster, and that the euro-normalised filing value is modest relative to market value. The score is not the story, though. The story is that a stock with improving fundamentals is now seeing directors sell into a better tape, while the company still has to prove that the cardiopulmonary strength and neuromodulation optionality can hold up beyond one clean quarter.

Large-cap cohort signals, and their limits

InsiderTrades data for director-level buys at large-cap names shows a 55.7% 90-day win rate and a 3.26% average return, with a 365-day average return of 89.18%. That is the historical bucket read. It is useful because it gives you a sense of how this role-and-size combination has behaved before. It is not a promise about LivaNova, and it is not a forecast for this director sale.

The comparison to Medtronic helps keep that straight. A larger, more diversified peer can make a director sale feel almost routine, because the business is so broad that one filing rarely changes the frame. LivaNova is narrower, so the same kind of filing can carry more weight in the market’s mind. That does not mean the cohort stat should be stretched into a thesis. It means the bucket tells you that director-level activity at large-cap names has historically been associated with a modestly positive 90-day profile, while this specific name still has to earn its own result.

The internal strategy framework is built for a 90-day hold window and a capped position size of 0.08% of capital. Its live headline tokens are 0.81, 26.4, and 51.5, but those sit on a restricted EU venue universe and do not survive search-aware deflation, so they belong in the background, not as a promise. The fundamental pillars are a transparent screen, not an alpha claim. That is enough to keep the framework honest without pretending it can tell you what LivaNova will do next.

The more useful question is whether the insider cluster and the operating momentum point in the same direction. They do not. The company is raising guidance. Directors are selling. That split is exactly why the filing matters. If the stock were weak and the board were buying, the read would be simpler. It is not simple here.

Boston Scientific sets the tougher standard

Boston Scientific is the tougher peer for LivaNova because it shows what a market favorite looks like in medtech. It has breadth, multiple growth engines, and enough scale to keep investors focused on execution rather than one product line. LivaNova does not need to become Boston Scientific. It does need to show that its narrower mix can still produce durable growth and margin discipline.

That is why the recent operating update matters more than the insider sale in the long run. Revenue growth of 10.8% to $390.6 million and raised constant-currency guidance to 8% to 9% are the kind of numbers that can keep a stock supported even when directors sell. The raised EPS guide to $4.30 to $4.40 adds another layer. If the company keeps delivering, the market will care less about a couple of sales. If growth slows, the same sales will look more pointed in hindsight.

The stock’s recent trading around $80 to $82 also matters because it gives the filing a price context. Story sold at $81.4218. Bianchi sold at $79.72. Those are not distressed prices. They are prices near where the market has been willing to clear the stock. That is why the comparison with Boston Scientific is useful. Bigger peers can absorb insider selling because the market is always watching the next franchise update. LivaNova has to keep the current story intact.

The company’s fundamental score in the dossier is 49, with a quality score of 57 and a value score of 40. That is a middling profile, not a disaster and not a screaming bargain. It fits the stock’s current position pretty well. The market is paying for execution, but not so much that a director sale gets ignored.

What to watch in the next earnings update

The next thing to watch is whether the cardiopulmonary momentum and neuromodulation growth continue to show up in the numbers. The August quarter gave the market a reason to stay engaged. The Thermo Fisher supply agreement gave it a reason to believe the cardiopulmonary side can keep moving. The raised guidance gave it a reason to keep the multiple from compressing too quickly.

The insider cluster gives you a reason to stay alert. Four distinct insiders, 12 recent declarations, and two director sales in late August and early September are enough to say that the board is not uniformly leaning into the stock at these levels. That does not make the shares unattractive. It makes them more conditional. If the next quarter confirms the current pace, the sales will look like routine monetization. If the pace slips, they will look better timed than the market would like.

Against Medtronic, LivaNova still looks like the smaller, more focused operator with a narrower set of levers. Against Boston Scientific, it looks like the company that has to keep proving that focus can be an advantage rather than a constraint. The insider filing does not settle that debate. It just tells you the board is happy to sell some stock while the operating story is still good enough to support the price.

That is the setup now. A company with raised guidance, a stock near the low $80s, and directors selling into strength. The next earnings update will tell you whether the market should keep giving LivaNova the benefit of the doubt.

Dig deeper: Story Brooke's filing track record.

This is not investment advice.